CN112516259A - Pharmaceutical composition for treating pneumonia and preparation method thereof - Google Patents
Pharmaceutical composition for treating pneumonia and preparation method thereof Download PDFInfo
- Publication number
- CN112516259A CN112516259A CN202011454538.1A CN202011454538A CN112516259A CN 112516259 A CN112516259 A CN 112516259A CN 202011454538 A CN202011454538 A CN 202011454538A CN 112516259 A CN112516259 A CN 112516259A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- treating pneumonia
- pneumonia
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 56
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 241000218671 Ephedra Species 0.000 claims abstract description 20
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 19
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 18
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 18
- 241000334160 Isatis Species 0.000 claims abstract description 18
- 235000014676 Phragmites communis Nutrition 0.000 claims abstract description 18
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 18
- 229910052602 gypsum Inorganic materials 0.000 claims abstract description 18
- 239000010440 gypsum Substances 0.000 claims abstract description 18
- 235000011477 liquorice Nutrition 0.000 claims abstract description 18
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 8
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 47
- 239000008187 granular material Substances 0.000 claims description 33
- 239000000463 material Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 19
- 244000144725 Amygdalus communis Species 0.000 claims description 16
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 16
- 235000020224 almond Nutrition 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 239000000080 wetting agent Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- 241000207929 Scutellaria Species 0.000 claims description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000013355 food flavoring agent Nutrition 0.000 claims description 8
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 6
- 240000009088 Fragaria x ananassa Species 0.000 claims description 6
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000004376 Sucralose Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 235000019408 sucralose Nutrition 0.000 claims description 6
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical group O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 108010011485 Aspartame Proteins 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000000605 aspartame Substances 0.000 claims description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 235000010357 aspartame Nutrition 0.000 claims description 4
- 229960003438 aspartame Drugs 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- 244000144730 Amygdalus persica Species 0.000 claims description 2
- 235000007270 Gaultheria hispida Nutrition 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 235000009134 Myrica cerifera Nutrition 0.000 claims description 2
- 244000269152 Myrica pensylvanica Species 0.000 claims description 2
- 235000012851 Myrica pensylvanica Nutrition 0.000 claims description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 206010011224 Cough Diseases 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 18
- 244000018633 Prunus armeniaca Species 0.000 abstract description 6
- 235000009827 Prunus armeniaca Nutrition 0.000 abstract description 6
- 208000006673 asthma Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 4
- 206010006451 bronchitis Diseases 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 238000001816 cooling Methods 0.000 abstract description 2
- 230000003467 diminishing effect Effects 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000035568 catharsis Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000005711 Benzoic acid Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000011812 mixed powder Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- CNLSPQQMAJCIFB-UHFFFAOYSA-N benzoic acid;ethanol Chemical compound CCO.OC(=O)C1=CC=CC=C1 CNLSPQQMAJCIFB-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating pneumonia and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The pharmaceutical composition disclosed by the invention is prepared from eight traditional Chinese medicines of scutellaria baicalensis, liquorice, ephedra, isatis root, gypsum, bitter apricot seed, reed rhizome and honeysuckle, and has the effects of pungent cooling and catharsis, lung clearing and asthma relieving, inflammation diminishing and cough relieving; the preparation method is simple and convenient to operate, retains effective components to the maximum extent, is particularly suitable for diseases such as acute pneumonia and acute bronchitis, and has definite clinical curative effect and small side effect.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a pharmaceutical composition for treating pneumonia and a preparation method thereof.
Background
Pneumonia is a common and multiple disease of the respiratory system, is usually caused by viruses and bacteria, and has clinical symptoms of cough, expectoration, asthma, fever, chest pain, hypodynamia, diarrhea and the like. If the patient can not be cured in time, asthma and dyspnea can be caused, various complications are caused, and the serious patient finally causes respiratory function to die due to exhaustion; not only brings great harm to patients, but also brings heavy burden to families and society. Clinically, the traditional western medicine treatment means is mainly adopted for symptomatic treatment, antiviral treatment, anti-infection treatment and the like, but the western medicine treatment means has certain limitations, for example, when the western medicine uses antibiotics and antiviral drugs for treatment, allergic symptoms are easy to generate or side effects are easy to cause or drug resistance is easy to generate; the complex diversity and drug resistance of the infectious pathogenic bacteria cause that the conventional western medicine treatment cannot achieve better treatment effect. A large amount of clinical evidence shows that compared with simple western medicine treatment, the adjuvant traditional Chinese medicine has safe and lasting effect of comprehensively preventing and treating the pneumonia. The traditional Chinese medicine emphasizes dialectical treatment and disease and symptom combination, and the traditional Chinese medicine and the compound preparation thereof have the characteristics of multiple components, multiple targets, difficult drug resistance generation and small toxic and side effects, and have more obvious advantages in the clinical treatment of pneumonia. The traditional Chinese medicine and the western medicine are combined to treat the pneumonia, so that the advantages are complemented, the clinical curative effect is improved, and a new way is brought to clinical treatment of the pneumonia.
The mixture refers to a water decoction concentrated solution of Chinese medicinal composition, or an oral liquid preparation prepared from Chinese medicinal extract with water as solvent; the mixture is developed and improved on the basis of decoction, maintains the characteristics of decoction, has small dosage compared with decoction, can be produced in batch, and avoids the troubles of temporary formulation and decoction. The Chinese medicinal granule is dry granular oral preparation prepared by processing fine powder or extract of Chinese medicinal materials and mixing with appropriate adjuvant or part of the fine powder of Chinese medicinal materials. The traditional Chinese medicine granule is a new traditional Chinese medicine formulation developed on the basis of decoction, not only maintains the advantages of quick absorption, quick effect and the like of the decoction, but also overcomes the defects of temporary decoction, time and energy consumption, easy mildewing, spoilage and the like after long-term storage before the decoction is taken.
Therefore, it is an urgent problem to provide a pharmaceutical composition for treating pneumonia and a preparation method thereof.
Disclosure of Invention
In view of the above, the present invention provides a pharmaceutical composition for treating pneumonia and a preparation method thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
a pharmaceutical composition for treating pneumonia comprises the following raw and auxiliary materials in parts by weight: 15-20 parts of gypsum, 15-20 parts of reed rhizome, (bitter) 10-15 parts of almond, 1-5 parts of ephedra, 15-20 parts of isatis root, (honeysuckle) 10-15 parts of liquorice, 10-15 parts of scutellaria baicalensis and 5-25 parts of auxiliary materials.
Further, the pharmaceutical composition is granules, the auxiliary materials comprise a diluent, a flavoring agent and a wetting agent, the diluent is 10-20 parts, the flavoring agent is 0.3-0.4 part, and the dosage of the wetting agent is 15-25% of the dosage of the raw and auxiliary materials except the wetting agent.
Further, the wetting agent is 85% -90% ethanol; the diluent is selected from at least one of maltodextrin, soluble starch, mannitol, microcrystalline cellulose and lactose; the flavoring agent is at least one of sweetener and solid essence.
Further, the sweetening agent is sucralose and aspartame; the solid essence is strawberry essence, juicy peach essence and waxberry essence.
Further, the pharmaceutical composition is a mixture, and the auxiliary material consists of 0.2-0.8 part of preservative.
Further, the preservative is at least one of 2% of nipagin and 10% of benzoic acid ethanol.
Further, a preparation method of the pharmaceutical composition for treating pneumonia comprises the following specific steps:
(1) weighing eight medicinal materials of gypsum, reed rhizome, (bitter) almond, ephedra herb, isatis root, (golden) honeysuckle flower, liquorice and baical skullcap root according to the weight;
(2) decocting in water twice, adding 3 times of water each time for 2 hours each time, mixing decoctions, filtering, and concentrating the filtrate to obtain fluid extract with relative density of 1.05-1.10 at 80-90 deg.C;
(3) adding 1-2 times of 95% ethanol, stirring, standing for 24 hours (winter room temperature) or 48 hours (summer room temperature), filtering, recovering ethanol from the filtrate, and adding adjuvants to obtain the pharmaceutical composition.
Further, a preparation method of the pharmaceutical composition for treating pneumonia is based on the steps (1) to (3) and further comprises the step (4): concentrating the filtrate under reduced pressure to obtain fluid extract with relative density of 1.2-1.3 at 55-65 deg.C, and further drying under reduced pressure to obtain dry extract powder; the temperature of the reduced pressure drying is 65-75 ℃, and the vacuum degree is 0.08-0.1 Mpa; adding a diluent and a flavoring agent into the dry paste powder, uniformly mixing, preparing wet granules by using 85% -90% ethanol as a wetting agent, drying at 50-70 ℃ for 1-3 h, and finishing granules to obtain the granules.
Further, a preparation method of the pharmaceutical composition for treating pneumonia is based on the steps (1) to (3) and further comprises the step (4): adding antiseptic into the filtrate, stirring, adding water to 30 parts, and packaging to obtain mixture.
According to the technical scheme, compared with the prior art, the invention discloses a pharmaceutical composition for treating pneumonia and a preparation method thereof, the pharmaceutical composition is composed of eight traditional Chinese medicines of scutellaria baicalensis, liquorice, ephedra, isatis root, gypsum, bitter apricot seed, reed rhizome and honeysuckle, and has the effects of cooling and ventilating, clearing away the lung-heat, relieving asthma, diminishing inflammation and relieving cough; the preparation method is simple and convenient to operate, retains effective components to the maximum extent, is particularly suitable for diseases such as acute pneumonia, acute bronchitis and the like, and has definite clinical curative effect and small side effect; it is also suitable for treating acute pneumonia and acute bronchitis of children.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the provided drawings without creative efforts.
FIG. 1 is a graph showing a statistical chart of cough latencies for groups of the present invention;
FIG. 2 is a graph showing a statistical chart of the number of coughs for each group according to the present invention;
figure 3 is a graph showing the critical relative humidity of the pneumonia particles of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A granule for treating pneumonia comprises the following raw and auxiliary materials in parts by weight: 18 parts of gypsum, 19 parts of reed rhizome, 15 parts of (bitter) almond, 4 parts of ephedra herb, 20 parts of isatis root, 14 parts of (golden) honeysuckle flower, 5 parts of liquorice, 13 parts of scutellaria baicalensis, 15 parts of lactose and 0.3 part of sucralose.
The preparation method of the granules for treating pneumonia comprises the following steps:
(1) weighing eight medicinal materials of gypsum, reed rhizome, (bitter) almond, ephedra herb, isatis root, (golden) honeysuckle flower, liquorice and baical skullcap root according to the weight;
(2) decocting in water twice, each time adding 3 times of water for 2 hr, mixing decoctions, filtering, and concentrating the filtrate to fluid extract with relative density of 1.05 at 80 deg.C;
(3) adding 95% ethanol 1 times, stirring, standing for 24 hr (winter room temperature) or 48 hr (summer room temperature), filtering, recovering ethanol from filtrate, concentrating the filtrate under reduced pressure to obtain fluid extract with relative density of 1.2 at 55 deg.C, and further drying under reduced pressure (65 deg.C, vacuum degree of 0.08Mpa) to obtain dry extract powder;
(4) adding lactose and sucralose into the dry extract powder, mixing, adding 90% ethanol as wetting agent with the addition amount of 25% of the total mixed powder, making into soft material, granulating with 16 mesh sieve, drying at 50 deg.C for 3 hr, and grading with 18 mesh sieve to obtain granule.
Example 2
A granule for treating pneumonia comprises the following raw and auxiliary materials in parts by weight: 15 parts of gypsum, 16 parts of reed rhizome, 12 parts of (bitter) almond, 1 part of ephedra herb, 17 parts of isatis root, 11 parts of (golden) honeysuckle flower, 2 parts of liquorice, 10 parts of scutellaria baicalensis, 10 parts of mannitol, 0.2 part of aspartame and 0.2 part of strawberry essence.
The preparation method of the granules for treating pneumonia comprises the following steps:
(1) weighing eight medicinal materials of gypsum, reed rhizome, (bitter) almond, ephedra herb, isatis root, (golden) honeysuckle flower, liquorice and baical skullcap root according to the weight;
(2) decocting in water twice, each time adding 3 times of water for 2 hr, mixing decoctions, filtering, and concentrating the filtrate to fluid extract with relative density of 1.10 at 90 deg.C;
(3) adding 2 times of 95% ethanol, stirring, standing for 24 hr (winter room temperature) or 48 hr (summer room temperature), filtering, recovering ethanol from filtrate, concentrating the filtrate under reduced pressure to fluid extract with relative density of 1.3 at 65 deg.C, and further drying under reduced pressure (75 deg.C, vacuum degree of 0.1Mpa) to obtain dry extract powder;
(4) adding mannitol, aspartame and strawberry essence into the dry extract powder, mixing, adding 85% ethanol as wetting agent, adding 15% of the total mixed powder, making into soft material, granulating with 16 mesh sieve, drying at 70 deg.C for 1 hr, and grading with 18 mesh sieve to obtain granule.
Example 3
A granule for treating pneumonia comprises the following raw and auxiliary materials in parts by weight: 19 parts of gypsum, 17 parts of reed rhizome, 10 parts of (bitter) almond, 5 parts of ephedra herb, 20 parts of isatis root, 14 parts of (golden) honeysuckle flower, 2 parts of liquorice, 13 parts of scutellaria baicalensis, 20 parts of lactose, 0.1 part of sucralose and 0.2 part of strawberry essence.
The preparation method of the granules for treating pneumonia comprises the following steps:
(1) weighing eight medicinal materials of gypsum, reed rhizome, (bitter) almond, ephedra herb, isatis root, (golden) honeysuckle flower, liquorice and baical skullcap root according to the weight;
(2) decocting in water twice, each time adding 3 times of water for 2 hr, mixing decoctions, filtering, and concentrating the filtrate to fluid extract with relative density of 1.10 at 90 deg.C;
(3) adding 95% ethanol 1.25 times, stirring, standing for 24 hr (winter room temperature) or 48 hr (summer room temperature), filtering, recovering ethanol from filtrate, concentrating the filtrate under reduced pressure to obtain fluid extract with relative density of 1.3 at 60 deg.C, and further drying under reduced pressure (70 deg.C, vacuum degree of 0.085Mpa) to obtain dry extract powder;
(4) adding lactose, sucralose and strawberry essence into the dry extract powder, mixing, using 90% ethanol as wetting agent, adding 20% of the total mixed powder, making into soft material, granulating with 16 mesh sieve, drying at 60 deg.C for 1h, and grading with 18 mesh sieve to obtain granule.
Example 4
A mixture for treating pneumonia comprises the following raw and auxiliary materials in parts by weight: 18 parts of gypsum, 19 parts of reed rhizome, 15 parts of (bitter) almond, 4 parts of ephedra herb, 20 parts of isatis root, 14 parts of (honeysuckle) flower, 5 parts of liquorice, 13 parts of baical skullcap root and 0.4 part of 2% nipagin.
The preparation method of the mixture for treating pneumonia comprises the following steps:
(1) weighing eight medicinal materials of gypsum, reed rhizome, (bitter) almond, ephedra herb, isatis root, (golden) honeysuckle flower, liquorice and baical skullcap root according to the weight;
(2) decocting in water twice, each time adding 3 times of water for 2 hr, mixing decoctions, filtering, and concentrating the filtrate to fluid extract with relative density of 1.05 at 80 deg.C;
(3) adding 1 time of 95% ethanol, stirring, standing for 24 hr (winter room temperature) or 48 hr (summer room temperature), filtering, recovering ethanol from filtrate, adding 0.4 part of 2% nipalgin, stirring, adding water to 30 parts, and packaging.
Example 5
A mixture for treating pneumonia comprises the following raw and auxiliary materials in parts by weight: 15 parts of gypsum, 16 parts of reed rhizome, 12 parts of (bitter) almond, 1 part of ephedra herb, 17 parts of isatis root, 11 parts of (golden) honeysuckle flower, 2 parts of liquorice, 10 parts of scutellaria baicalensis and 0.3 part of 10% benzoic acid.
The preparation method of the mixture for treating pneumonia comprises the following steps:
(1) weighing eight medicinal materials of gypsum, reed rhizome, (bitter) almond, ephedra herb, isatis root, (golden) honeysuckle flower, liquorice and baical skullcap root according to the weight;
(2) decocting in water twice, each time adding 3 times of water for 2 hr, mixing decoctions, filtering, and concentrating the filtrate to fluid extract with relative density of 1.1 at 90 deg.C;
(3) adding 2 times of 95% ethanol, stirring, standing for 24 hr (winter room temperature) or 48 hr (summer room temperature), filtering, recovering ethanol from filtrate, adding 0.3 part of 10% benzoic acid, stirring, adding water to 30 parts, and packaging.
Example 6
A mixture for treating pneumonia comprises the following raw and auxiliary materials in parts by weight: 19 parts of gypsum, 17 parts of reed rhizome, 10 parts of (bitter) almond, 5 parts of ephedra herb, 20 parts of isatis root, 14 parts of (honeysuckle) honeysuckle, 2 parts of liquorice, 13 parts of baical skullcap root, 0.3 part of 2 percent nipagin and 0.3 part of 10 percent benzoic acid.
The preparation method of the mixture for treating pneumonia comprises the following steps:
(1) weighing eight medicinal materials of gypsum, reed rhizome, (bitter) almond, ephedra herb, isatis root, (golden) honeysuckle flower, liquorice and baical skullcap root according to the weight;
(2) decocting in water twice, each time adding 3 times of water for 2 hr, mixing decoctions, filtering, and concentrating the filtrate to fluid extract with relative density of 1.1 at 90 deg.C;
(3) adding 1.25 times of 95% ethanol, stirring, standing for 24 hr (winter room temperature) or 48 hr (summer room temperature), filtering, recovering ethanol from filtrate, adding 0.3 part of 2% nipagin and 0.3 part of 10% benzoic acid, stirring, adding water to 30 parts, and packaging.
Test example 1 cough relieving effect of granules for treating pneumonia on ammonia-induced mouse cough model
The purpose is as follows: the cough relieving effect of the examples 1 to 6 on the model of mice cough caused by ammonia water is observed
The tested drugs are: the pneumonia granule or mixture and the ephedra and apricot cough syrup prepared in the examples 1 to 6 are positive Chinese medicines.
The method comprises the following steps: cough is one of the main symptoms of pneumonia, the experiment adopts strong ammonia water to stimulate mice to induce cough reaction, and the cough suppressing effect of the tested medicine is evaluated by taking the cough incubation period of the mice and the cough frequency within 5min as the indexes of the cough suppressing effect. ICR mice were randomly divided into a model group, a positive drug substance, namely, a sesame and apricot cough syrup group, examples 1 to 3 (administration dose: 4.7g/kg, which is converted into a mouse administration dose according to a clinical administration dose), and examples 4 to 6 (administration dose: 7.8ml/kg, which is converted into a mouse administration dose according to a clinical administration dose). Except the model group, the other groups are respectively administered with normal saline by gavage administration according to the administration dosage design of the mice, the corresponding drugs are administered by gavage administration for 1 time and 7 days continuously every day, after the last gavage for 1 hour, the animal model is established by inducing cough by adopting strong ammonia water, and the latency period of the cough beginning to appear in the mice and the cough frequency within 5min are observed and recorded.
As a result: the model group mice showed obvious cough, the number of cough within 5min reaches 20.71 +/-6.40, and the cough latency period is 76.71 +/-22.77(s). The positive drug of the apricot kernel cough syrup group obviously reduces the cough frequency of mice caused by ammonia water (p is less than 0.001, VS model group), and simultaneously obviously prolongs the cough latency time of the mice (p is less than 0.05, VS model group). The pneumonia cocktail groups (examples 4-6) significantly reduced the number of coughs in mice due to ammonia (p <0.001, VS model group) while significantly extended the latency of coughs in mice (p <0.05, VS model group). The pneumonia granule group (examples 1-3) significantly reduced the number of coughs in mice caused by ammonia (p <0.001, VS model group), while significantly prolonged the latency of coughs in mice (p <0.05, VS model group). The result shows that the pneumonia granule and the pneumonia mixture obtained by the invention have obvious effect of inhibiting the cough of mice caused by ammonia water, simultaneously prolong the latent time of cough and have the effect equivalent to that of the ephedra and apricot cough syrup. The effect of the pneumonia granule and the mixture obtained by the invention on the mouse cough model caused by ammonia water is shown in table 1 and figures 1-2.
TABLE 1 comparison of cough latency and cough frequency in groups of mice
Note: experimental data on
It is shown that,*p<0.05,**p<0.01,***p<0.001vs model set.
Test example 2 verification test for reliability and stability of preparation method
3 parts of the granules prepared in examples 1 to 3 were taken, and the molding ratio, solubility, hygroscopicity and angle of repose were measured.
(1) Measurement of Molding Rate
Weighing the prepared particles, firstly sieving the particles by a first sieve, then sieving the particles by a fifth sieve, collecting the particles which can pass through the first sieve but can not pass through the fifth sieve, and weighing the particles.
The molding rate is the mass of the particles after sieving/the mass before sieving multiplied by 100 percent
(2) Determination of solubility
10g of each of the granules prepared in examples 1 to 3 was added to 200mL of hot water, stirred for 5 minutes, and immediately observed that all the granules were melted or suspended, and soluble granules were melted and allowed to slightly precipitate. Drying the precipitate to constant weight, precisely weighing, and calculating the dissolution rate of the particles.
Melting rate (%). ratio (weight of melted particles/weight of particles) × 100%
(3) Investigation of moisture absorption
2g of the granules prepared in examples 1 to 3 were weighed precisely and placed in a flat weighing bottle having a constant weight, precisely weighed, stored in a constant temperature incubator at a temperature of 25 ℃ and a relative humidity of 75% (NaCl was periodically put in a glass drier having a saturated NaCl solution at the bottom until a supersaturated NaCl solution was formed), and the moisture absorption percentage was calculated as a moisture absorption percentage at 48 hours, and it was generally satisfactory that the moisture absorption percentage was less than 5%.
Percent moisture absorption (weight of post-moisture-weight of pre-moisture-absorption particle)/weight of pre-moisture-absorption particle × 100%
(4) Determination of the angle of repose
Experimental procedure using the fixed funnel method, 3 funnels were connected in series and fixed at lcm height on a horizontally placed graph paper, the particles prepared in examples 1-3 were carefully poured into the uppermost funnel along the funnel wall until the tip of the cone formed on the graph paper contacted the lower mouth of the funnel, the diameter of the cone bottom (2r) was measured from the graph paper, and calculated: the angle of repose tg α is H/r. Do 5 times and calculate the average.
3 portions of granules prepared in examples 1 to 3 were measured for 3 lots, respectively, by the above-described method; wherein, the result of the forming rate of 3 batches of the granules prepared in the example 1 is 92.0% + -0.3%; all the pneumonia particles of 3 batches are dissolved, and no precipitate is generated after standing for a moment; the moisture absorption percentage result of 3 batches of pneumonia particles is 7.5% + -2.9%; the angle of repose results for 3 pneumonia particles were 17.1 ° ± 0.5 °; the granule formulation 3 batches prepared in example 2 gave a forming rate result of 96.4% + -0.6%; all the pneumonia particles of 3 batches are dissolved, and no precipitate is generated after standing for a moment; the moisture absorption percentage result of 3 batches of pneumonia particles is 1.9% + -0.1%; the angle of repose result of 3 batches of pneumonia particles is 7.1 degrees +/-0.1 degrees, which indicates that the preparation method of the invention is stable and feasible.
Test example 3 measurement of Critical Relative Humidity (CRH) of particles
Critical relative humidity studies were performed on the pneumonia particles prepared as described in example 1 above. Supersaturated solutions of different salts are prepared in different glass dryers according to the table 1, the glass dryers are placed for 48 hours at room temperature, the internal humidity of the glass dryers reaches a balanced state, namely, under the environment of different RH, about 1g of sample particles are placed at the bottom of a weighing bottle with constant mass and are uniformly spread, the sample particles are respectively placed in the dryers containing the different supersaturated solutions, a weighing bottle cap is opened, the glass dryers are placed in a constant temperature incubator for 7 days at 25 ℃, then the moisture absorption rates of the particles are precisely weighed and calculated, and the results are shown in the table 2. Respectively drawing by taking RH as an abscissa and moisture absorption rate of the particles as an ordinate, drawing tangent lines to the curve along two ends of the curve, and obtaining the abscissa corresponding to the intersection point of the two tangent lines as CRH of the particles. From FIG. 3, the CRH of the particles was 73%. The granules hardly absorb moisture in the environment with the relative humidity lower than 73 percent, and the moisture absorption amount is increased sharply when the relative humidity is higher than 73 percent, so that the environmental humidity needs to be controlled below 73 percent during granulation, subpackaging and storage so as to reduce the influence of the moisture on the property and the stability of the medicine.
TABLE 2 determination of moisture absorption Rate at different relative humidities
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (9)
1. The pharmaceutical composition for treating pneumonia is characterized by comprising the following raw and auxiliary materials in parts by weight: 15-20 parts of gypsum, 15-20 parts of reed rhizome, (bitter) 10-15 parts of almond, 1-5 parts of ephedra, 15-20 parts of isatis root, (honeysuckle) 10-15 parts of liquorice, 10-15 parts of scutellaria baicalensis and 5-25 parts of auxiliary materials.
2. The pharmaceutical composition for treating pneumonia according to claim 1, wherein the pharmaceutical composition is a granule, the adjuvant is composed of a diluent, a flavoring agent and a wetting agent, the diluent is 10-20 parts, the flavoring agent is 0.3-0.4 part, and the amount of the wetting agent is 15-25% of the amount of the raw and auxiliary materials except the wetting agent.
3. The pharmaceutical composition for treating pneumonia according to claim 2, wherein said wetting agent is 85% -90% ethanol; the diluent is selected from at least one of maltodextrin, soluble starch, mannitol, microcrystalline cellulose and lactose; the flavoring agent is at least one of sweetener and solid essence.
4. The pharmaceutical composition for the treatment of pneumonia according to claim 3, wherein said sweetener is sucralose, aspartame; the solid essence is strawberry essence, juicy peach essence and waxberry essence.
5. The traditional Chinese medicine composition for treating pneumonia according to claim 1, wherein the medicine composition is a mixture, and the adjuvant consists of 0.2-0.8 parts of preservative.
6. The pharmaceutical composition for treating pneumonia according to claim 5, wherein said preservative is at least one of 2% paraben, 10% benzoic alcohol.
7. The preparation method of the pharmaceutical composition for treating pneumonia according to claim 1, is characterized by comprising the following steps:
(1) weighing eight medicinal materials of gypsum, reed rhizome, (bitter) almond, ephedra herb, isatis root, (golden) honeysuckle flower, liquorice and baical skullcap root according to the weight;
(2) decocting in water twice, adding 3 times of water each time for 2 hours each time, mixing decoctions, filtering, and concentrating the filtrate to obtain fluid extract with relative density of 1.05-1.10 at 80-90 deg.C;
(3) adding 1-2 times of 95% ethanol, stirring, standing for 24 hours (winter room temperature) or 48 hours (summer room temperature), filtering, recovering ethanol from the filtrate, and adding adjuvants to obtain the pharmaceutical composition.
8. The method for preparing a pharmaceutical composition for treating pneumonia according to claim 2, based on steps (1) - (3) of claim 7, further comprising step (4): concentrating the filtrate under reduced pressure to obtain fluid extract with relative density of 1.2-1.3 at 55-65 deg.C, and further drying under reduced pressure to obtain dry extract powder; the temperature of the reduced pressure drying is 65-75 ℃, and the vacuum degree is 0.08-0.1 Mpa; adding a diluent and a flavoring agent into the dry paste powder, uniformly mixing, preparing wet granules by using 85% -90% ethanol as a wetting agent, drying at 50-70 ℃ for 1-3 h, and finishing granules to obtain the granules.
9. The method for preparing a pharmaceutical composition for treating pneumonia according to claim 5, based on steps (1) - (3) of claim 7, further comprising step (4): adding antiseptic into the filtrate, stirring, adding water to 30 parts, and packaging to obtain mixture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011454538.1A CN112516259A (en) | 2020-12-10 | 2020-12-10 | Pharmaceutical composition for treating pneumonia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011454538.1A CN112516259A (en) | 2020-12-10 | 2020-12-10 | Pharmaceutical composition for treating pneumonia and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112516259A true CN112516259A (en) | 2021-03-19 |
Family
ID=74998872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011454538.1A Pending CN112516259A (en) | 2020-12-10 | 2020-12-10 | Pharmaceutical composition for treating pneumonia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112516259A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895395A (en) * | 2006-06-12 | 2007-01-17 | 刘雅芹 | Xiaoer Kechuanling soft extract for treating infantile cough and asthma and its preparing method |
| CN103623088A (en) * | 2013-12-05 | 2014-03-12 | 江苏恒丰强生物技术有限公司 | Ephedra, almond gypsum and licorice granule pill |
-
2020
- 2020-12-10 CN CN202011454538.1A patent/CN112516259A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895395A (en) * | 2006-06-12 | 2007-01-17 | 刘雅芹 | Xiaoer Kechuanling soft extract for treating infantile cough and asthma and its preparing method |
| CN103623088A (en) * | 2013-12-05 | 2014-03-12 | 江苏恒丰强生物技术有限公司 | Ephedra, almond gypsum and licorice granule pill |
Non-Patent Citations (1)
| Title |
|---|
| 吴红霞等: "RP-HPLC法测定肺炎合剂中盐酸麻黄碱的含量", 《新疆医学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101099729B (en) | Oral solid preparation containing ambroxol hydrochloride and salbutamol active components | |
| CN1861153A (en) | Medicinal composition used for treating pharyngitis, its prepn. method and its quality control method | |
| CN111358839B (en) | Formula granules of polygonum capitatum and preparation method thereof | |
| CN101254249B (en) | Chinese and Western compound preparations for curing cough and abundant sputum symptoms and method of preparing the same | |
| CN112274602A (en) | Cold heat clearing granules and preparation method thereof | |
| WO2012027968A1 (en) | Panaxatriol saponins enteric pellet, capsule comprising same and method for preparing same | |
| CN100386093C (en) | Medicine composition for treating cold and upper respiratory tract infection, preparation method and purpose thereof | |
| CN116942743A (en) | Preparation method of Ganmaoqing tablet and product thereof | |
| CN109966395B (en) | Soft capsule for treating acute bronchitis cough of children | |
| CN112516259A (en) | Pharmaceutical composition for treating pneumonia and preparation method thereof | |
| CN113827570B (en) | Method for preparing traditional Chinese medicine pellet preparation based on drug carrier technology and application thereof | |
| CN101966316A (en) | Gujin pill pellet and preparation method thereof | |
| CN1943734B (en) | A Chinese traditional medicine for clearing away heat and toxic material | |
| CN105920199A (en) | Traditional Chinese medicinal composition for treating pulmonary infection, oral fast dissolving membrane and preparation method thereof | |
| CN112656869B (en) | Composition for treating lung-heat cough and asthma, preparation method and application | |
| CN101647885B (en) | Medicine composition for treating coughs | |
| CN113413366A (en) | Dry-suspension oral in-situ gel for treating chronic gastritis and preparation method thereof | |
| CN103041079B (en) | Preparation method of sugar-free Masu anti-cough compound preparation | |
| CN107898942B (en) | Cold clearing capsule and preparation method thereof | |
| WO2019227885A1 (en) | Capsule preparation of achyranthes aspera l. var. rubrafusca (wight) hook polysaccharide, preparation method, and applications | |
| CN111358875A (en) | Traditional Chinese medicine composition for treating gastroesophageal reflux cough and preparation method thereof | |
| CN115645490B (en) | Tablet for pharyngitis and preparation method thereof | |
| CN110859945B (en) | Capsule for preventing and treating ankylosing spondylitis and preparation method thereof | |
| CN114376978B (en) | Doxofylline-coated chip and preparation method thereof | |
| CN100496564C (en) | Chinese remedy medicinal dry-mixed suspension preparation for treating cold and preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210319 |